After 13 years, international Infectious Diseases and Respiratory Medicine societies have jointly issued new recommendations for the treatment of patients with nontuberculous mycobacteria (NTM). Curre
Gülşah Gabriel and Stefan Niemann impressed the judges with their scientific work: The German Center for Infection Research (DZIF) is awarding them both a translational infection research prize worth
The working group runs a platform to evaluate the efficacy of new drugs and to select optimal treatment options for tuberculosis patients. In vitro test systems are available for preclinical testing, which are used to test the activity of substances against tuberculosis-causing mycobacteria. An ...
The first antibiotic against tuberculosis that has been developed in Germany is now ready for clinical testing. BTZ043, as the newly developed drug substance is called, is also effective against
The National Reference Center at the Research Center Borstel has confirmed a Europe-wide outbreak of a multidrug-resistant Mycobacterium tuberculosis strain in 29 refugees from the Horn of Africa. The
Scientists from a European Consortium reconstructed a global Mycobacterium chimaera outbreak by whole genome sequencing. The report has identified contaminated heater-cooler units as the likely source
Tuberculosis is one of the most important infectious diseases worldwide. Treatment is lengthy and challenging. Doctors and scientists at the DZIF Clinical Center for Tuberculosis develop new therapies
According to figures of the World Health Organization, some 8.7 million people contracted tuberculosis in 2012 and this disease is fatal for approximately 1.3 million people throughout the world each
